Evidence map›Paper›PMID 41431893›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

De Novo Gene Transcription of Connexin Mediates Cytoplasmic Fluid Exchange and Flocking Transitions in Physiological and Cancerous Epithelial Systems.

Hind Abdo, Leonardo Barzaghi, Yuan Shen, Edoardo Bellini, Emanuele Martini, Serena Magni, Sara Barozzi, Fabrizio Orsenigo, Dario Parazzoli, Galina V Beznoussenko and 9 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hind AbdoIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Leonardo BarzaghiIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Yuan ShenUniversite Paris Cite, CNRS, Institut Jacques Monod, Paris, F-75013, France.
Edoardo BelliniIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Emanuele MartiniIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Serena MagniIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Sara BarozziIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Fabrizio OrsenigoIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Dario ParazzoliIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Galina V BeznoussenkoIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Jasmin Di FrancoFaculty of Physics, University of Vienna, Vienna, 1010, Austria.
Fabian KrautgasserTurku Bioscience Center, University of Turku and Åbo Akademi University, Turku, FI-20520, Finland.
Jasmin KaivolaVienna Doctoral School in Physics, University of Vienna, Vienna, 1010, Austria.
Mario CinquantaCogentech Società Benefit srl, via Adamello 16, Milan, 20139, Italy.
Alessandro LazzarinIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.
Sara SigismundDepartment of Oncology and Haemato-Oncology, University of Milan, Milan, 20122, Italy.
Johanna IvaskaTurku Bioscience Center, University of Turku and Åbo Akademi University, Turku, FI-20520, Finland.
Roberto CerbinoFaculty of Physics, University of Vienna, Vienna, 1010, Austria.
Giorgio ScitaIFOM, the FIRC Institute of Molecular Oncology, Milan, 20139, Italy.ORCID https://orcid.org/0000-0001-7984-1889

Funding

AIRC IG 2022 - ID 27101AIRC IG ERC-CoG2020 #101002280AIRC IG IG #24415AIRC-IG #22821AIRC-IG 5X1000 (#22759Fondazione Veronesi Post-doctoral fellowshipHORIZON EUROPE European Research Council 801 101071470Italian Ministry of HealthItalian Ministry of University and Research COMBINE/G53D23007040001/P2022RH4HH002Italian Ministry of University and Research PNRR_CN3RNA_SPOKE/G43C22001320007Italian Ministry of University and Research PRIN202223GSCIT_01/G53D23002570006/20229RM8A_001Italian Ministry of University and Scientific Research 2022W93FTWItalian Ministry of University and Scientific Research PRIN 2022
6 · The paper itself

Abstract

The initial invasion of tumors requires a transition from a solid, jammed state to a fluid-like, flocking, unjammed state that enables collective migration. Here, we show that de novo gene transcription is essential for the emergence of flocking in epithelial tissues and identify connexins (Cx) as key mediators of this transition. Using quiescent HaCaT keratinocytes, tumorigenic A431 epidermoid carcinoma cells, primary bronchial epithelial explants, and vocal fold carcinoma (VFC) cells, we find that flocking induction depends on transcriptional programs activated downstream of epidermal growth factor (EGF). EGF stimulation upregulates Cx26 and Cx31 and enhances gap-junctional intercellular communication (GJIC), which is necessary-though not sufficient-to generate the large-scale cell-volume fluctuations and density heterogeneity that accompany unjamming. Sustained signaling through extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT serine/threonine kinase (AKT) downstream of the EGF receptor (EGFR) is required for connexin induction, linking mechanical state transitions to extracellular cues. Pharmacological inhibition and CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR associated protein 9) knockout of connexins block unjamming and collective motility. VFC cells display constitutively elevated connexins and persistent flocking that is highly sensitive to connexin inhibition. Consistently, high Cx26 expression correlates with reduced survival across carcinomas. These findings reveal a transcriptionally controlled, connexin-dependent mechanism that enables tissue fluidization and collective invasion.

Indexed as

ConnexinsTranscription, GeneticCell CommunicationCell Line, TumorCell MovementConnexin 26Epidermal Growth FactorEpithelial CellsGap JunctionsHumansSignal TransductionConnexin 26ConnexinsEpidermal Growth Factorcollective motilityconnexins and fluid exchangeEGFR signalingjamming transitiontissue‐level phase transition

Identifiers

PMID41431893
PMCPMC12866692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.